# In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma

Source: https://onco.cc/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/  
OnCo record `idea-reg-in-vivo-cart-off-the-shelf-vial` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some new medicines reprogramme immune cells inside the body with an injection, skipping the factory entirely. Test whether that makes CAR-T affordable and available in ordinary hospitals.

## Summary

In vivo CAR-T uses targeted lipid nanoparticles or engineered lentiviral vectors to deliver the CAR gene to T cells inside the patient (programmes from Interius, Umoja, Orna, Capstan and others entered the clinic in 2024-25). This idea is not about which antigen to hit but about manufacturing and delivery economics: a frozen vial produced in batches of thousands, administered in a community hospital with no apheresis, no bridging chemotherapy and possibly no lymphodepletion. A companion idea in this corpus covers solid-tumour antigens.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: An in vivo CD19 CAR-T product can be produced at a cost of goods below $10,000 per dose and delivered in non-academic centres with complete response rates in relapsed B-cell lymphoma within 15 percentage points of autologous CAR-T, and with a shorter time from decision to treatment.
- Rationale: Batch manufacture of a nucleic acid-lipid product is the same industrial process that produced billions of mRNA vaccine doses; the marginal cost is orders of magnitude below a bespoke cell product, and the logistics collapse to a cold chain.
- Proposed test: Phase 2 in relapsed large B-cell lymphoma at community and academic sites, with pre-specified endpoints for cost of goods, time from enrolment to infusion, and response rate; compare with matched autologous CAR-T recipients.
- Maturity: early-clinical
- Actor: industry

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- ideas: [In vivo CAR-T against solid-tumour antigens](https://onco.cc/ideas/idea-in-vivo-car-solid/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Interius BioTherapeutics](https://onco.cc/companies/interius/), [Orna Therapeutics (Eli Lilly)](https://onco.cc/companies/orna-therapeutics/), [Umoja Biopharma](https://onco.cc/companies/umoja-biopharma/)
- trials: [RELIANCE](https://onco.cc/trials/reliance/), [Study of Out of Specification for Tisagenlecleucel](https://onco.cc/trials/nct04094311/), [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/), [ZUMA-1](https://onco.cc/trials/zuma-1/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/)
- key papers: [Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials](https://onco.cc/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/), [SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies](https://onco.cc/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/), [The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19](https://onco.cc/key-papers/paper-cd19-dlbcl-cytotherapy-2020/), [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-in-vivo-cart-off-the-shelf-vial.json